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Forced Feeding: New Legal Issues in the 
Biotechnology Policy Debate 
Neil D. Hamilton* 
INTRODUCTION: LOOKING BACK TO MOVE AHEAD 
In the fall of 2000, I presented a paper, Legal Issues Shaping 
Society’s Acceptance of Biotechnology and Genetically Modified 
Organisms,1 at the American Agricultural Law Association annual 
meeting in St. Louis. The paper inventoried the legal and policy 
issues shaping America’s approach toward biotechnology and was 
designed to serve as a tool for understanding the ongoing debate. 
Thirty months have passed and the pace of consideration of issues 
relating to society’s acceptance of biotechnology has not slowed. Just 
as the article was being finished, the StarLink fiasco was beginning. 
That episode alone has provided the grist for numerous lawsuits and 
other policy debates.2  
In the intervening thirty months, several issues have become more 
settled. For example, except for skirmishes such as the failed ballot 
referendum in Oregon to mandate food labels,3 American consumers 
appear for the most part to accept the Food and Drug 
Administration’s decision not to require labeling on the use of 
genetically modified ingredients. In light of the obstacles the FDA 
placed in the way of anyone trying to label a food as being free of 
 * Professor Hamilton is the Dwight D. Opperman Chair of Law and Director, 
Agricultural Law Center, Drake University Law School, Des Moines, Iowa. 
 1. Neil Hamilton, Legal Issues Shaping Society’s Acceptance of Biotechnology and 
Genetically Modified Organisms, 6 DRAKE J. AGRIC. L. 81 (2001). This article subsequently 
received the American Agricultural Law Association’s Award of Excellence for Professional 
Scholarship at the association’s October 2002 meeting.  
 2. See Kramer v. Aventis Crop Sci. USA Holding, Inc., 212 F. Supp. 2d 828 (N.D. Ill. 
2002).  
 3. See, e.g., Philip Brasher, Oregon Voters Reject Food-Labeling Measure, DES MOINES 
REG., Nov. 8, 2002, at 1D. 
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Genetically Modified Organisms (GMO), it may not be surprising the 
issue has subsided.4 Other issues, such as the continuing conflict 
between the United States and the European Union over European 
resistance to accepting unlabeled GMO foods and the legality of such 
action under the World Trade Organization (WTO) rules, remain 
topics of current public debate.5 Predictably, several new issues have 
emerged which were not addressed in the original article, the most 
significant being the controversy over planting pharma-crops, 
traditional commodities genetically modified to create traits and 
products with pharmacological value.6 
What follows is an effort both to update many of the issues 
discussed in the previous article and to make the analysis more timely 
and complete. In doing so, the article will share whatever insights and 
observations are possible concerning the role that biotechnology will 
play in our food and agriculture system and how policy and law will 
be asked to shape that future.  
RECENT DEVELOPMENTS IN BIOTECHNOLOGY POLICY—WHAT HAS 
WORKED AND WHAT HASN’T 
Before discussing recent policy developments relating to 
agricultural biotechnology, it may be helpful to start with a brief 
summary of events from the last two years. On the domestic front, the 
public acceptance of biotechnology has continued with only a few 
minor interruptions. From the standpoint of farms, the continued and 
rapid adoption of genetic modification (GM) technology—especially 
in the form of Roundup Ready soybeans and Bacillus thuringiensis 
(Bt) corn—is remarkable.7 This seems especially so in light of the 
 4. See Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have or 
Have Not Been Developed Using Bioengineering, 66 Fed. Reg. 4839 (Jan. 18, 2001), available 
at http://www.cfsan.fda.gov/~dms/biolabgu.html. 
 5. See, e.g., Philip Brasher, Biotech Ban Tries Patience of U.S., DES MOINES REG., Mar. 
4, 2003, at 1D (concerning Trade Representative Robert Zoellick’s frustration that current 
geopolitical forces relating to U.S. plans to invade Iraq have for now led the U.S. to delay its 
plans to file a formal WTO complaint against E.U. policy on GMO foods). 
 6. E.g., Philip Brasher, U.S. Tightens Rules for Growing Pharma Crops, DES MOINES 
REG., Mar. 7, 2003, at 1D. 
 7. See, e.g., ERS Research Identifies Benefits, Costs to Farmers of Using GE Crops, 
FEEDSTUFFS, Aug. 26, 2002, at 3 (discussing the recent report by United States Department of 
Agriculture economists documenting the rapid adoption of genetically engineered crops, 
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continuing uncertainty whether some foreign markets will accept the 
crops. In particular, the resistance of European consumers to 
accepting gene-altered food appears to have hardened, perhaps as a 
method of resisting what is seen as America’s attempted political and 
economic hegemony.8 Around the world the use and development of 
biotechnology continues to progress, with Asia being an especially 
active region.9 The continued development of new crop products by 
the biotech sector, such as the recently approved version of Bt corn 
for use with corn root-worm, a major pest in the United States, 
promises a continued flush of new products for use by farmers.10  
As to the actual farm-level use of biotechnology, the main focus is 
on three issues: resistance management for Bt crops,11 lingering 
concerns about how to resolve liability conflicts between biotech and 
non-biotech crops such as organic grain, and the potential use and 
regulation of pharma-crops.12 From a legal perspective, recent 
litigation involving the StarLink episode has begun to provide some 
of the legal guidance that will be needed to resolve the unavoidable 
conflicts between production of biotech crops and non-GMO crops.13 
From an industry perspective, the resolution of intellectual property 
including sixty-one percent of the U.S. soybean crop and fifty-six percent of the cotton crop in 
2001).  
 8. See Lizette Alvarez, Consumers in Europe Resist Gene-Altered Foods, N.Y. TIMES, 
Feb. 11, 2003, at A3.  
 9. See David Barboza, Development of Biotech Crops Is Booming in Asia, N.Y. TIMES, 
Feb. 21, 2003, at A3 (reporting that China, India, and Indonesia are already planting millions of 
acres of GMO crops and are investing heavily in developing locally adapted GM products).  
 10. See Philip Brasher, EPA Gives Final OK to New Corn, DES MOINES REG., Feb. 26, 
2003, at 1D; Andrew Pollack, U.S. Approves Type of Corn That May Cut Pesticide Use, N.Y. 
TIMES, Feb. 26, 2003, at C10.  
 11. See, e.g., Growers Must Follow Bt Planting Guidelines or Be Denied Seed, IOWA 
FARM BUREAU SPOKESMAN, Nov. 23, 2002, at H10. 
 12. The USDA has announced much-awaited rules for the planting of pharma-crops. See 
Philip Brasher, U.S. Tightens Rules for Growing Pharma Crops, DES MOINES REG., Mar. 7, 
2003, at 1D; Andrew Pollack, U.S. Imposes Stricter Rules for Genetically Modified Crops, N.Y. 
TIMES, Mar. 7, 2003, at A23. These rules, which include enhanced on-farm inspections 
requirements and limitations on the ability to rotate food crops on fields recently planted with 
pharma-crops, may have the effect of limiting the use of the technology in Midwestern states 
like Iowa. Field Testing of Plants Engineered to Produce Pharmaceutical and Industrial 
Compounds, 68 Fed. Reg. 11,337 (Mar. 10, 2003) (to be codified at 7 C.F.R. pt. 340).  
 13. An excellent example of the costs and complexities involved in managing the inherent 
conflicts between these production systems can be seen in the recent $110 million settlement of 
claims by non-StarLink growers. See Non-StarLink Farmer Litigation, at http://non-
starlinkfarmerssettlement.com (last visited Nov. 14, 2004). 
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rights issues means the real legal and policy issues will relate to how 
the federal government proceeds with implementation of new 
regulations on farmers’ use of the products—such as the required 
refuges to manage resistance and limitations on producing pharma-
crops in rotation. In summary, the horizon is relatively bright with 
only a few clouds looming to challenge the continued growth and 
acceptance of biotechnology in American agriculture and our food 
system. Farmers are planting, American consumers are eating, and 
most foreign customers are buying. At least for now everything is 
relatively peaceful. Whether the future proves to be so tranquil will 
depend in part on how the legal issues summarized in the following 
eight categories play out.  
I. African Famine Provides New Opportunity to Attack Biotech 
Opponents—If We Don’t Use It, People Will Die! 
The international development that provided perhaps the strongest 
opportunity for proponents of biotechnology to argue its benefits, and 
perhaps as importantly to castigate its opponents, came from an 
unlikely source: the need for increased food aid to relieve famines in 
southern Africa.14 As America and other grain producing nations 
mobilized to respond to the need for grain, several potential recipient 
nations questioned whether the food aid, in particular corn in seed 
form rather than ground as meal, would contain GMOs. The debate 
brought into focus the contrast between American attitudes toward 
the safety of the crops and the further trade related impact of the 
leakage of seeds into production. Because the United States grain 
marketing system does not segregate or identify the type of corn, and 
given the increased prevalence of the planting of GMO seeds, the 
assumption would have to be that American food aid would contain 
GMOs. The issue for several African nations then became whether 
the risk of accepting the food aid—knowing at least some of the corn 
would be diverted and saved for seed and replanted—would lead to 
 14. See, e.g., Henri E. Cauvin, Between Famine and Politics, Zambians Starve, N.Y. 
TIMES, Aug. 30, 2002, at A6; Henri E. Cauvin, Zambian Leader Defends Ban on Genetically 
Altered Foods, N.Y. TIMES, Sept. 4, 2002, at 6; Marc Lacey, Engineering Food for Africans, 
N.Y. TIMES, Sept. 8, 2002, at A16. 
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the presence of GMO corn in future crops.15 The concern was how 
this development might affect a nation’s status as “GMO free” for 
purposes of future sales to European countries and other countries 
concerned about GMOs. 
The debate over these issues mushroomed into an international 
incident which illuminated several ethical issues. For instance, could 
a nation such as Zambia refuse food aid knowing that people might 
die rather than accept GMO crops, which have no known food safety 
risks for consumers?16 On closer study, the food shortages appear to 
have subsided, except in Zimbabwe.17 But the underlying conflict 
provided rich fodder for American policy makers and biotechnology 
promoters looking for an argument to throw back at Europeans 
resisting the use of GMOs.18 Rather than simply alleging that the 
European Union’s resistance stems from trade preferences or anti-
technology elitism, United States officials, most notably Trade 
Representative Robert B. Zoellick, are now able to accuse the 
Europeans of callous disregard and active culpability in starving poor 
Africans solely to protect their sensitivities over eating GMOs. For 
example, Mr. Zoellick was quoted as saying, “I find it immoral that 
people are not being able to be supplied food to live in Africa 
because people have invented dangers about biotechnology.”19 While 
the Europeans protested they had not pressured African nations and 
do not promote starvation, the moral issue was joined.20  
 15. See supra note 14. 
 16. See, e.g., Rekha Basu, Africans’ Logical Fear of GM Corn, DES MOINES REG., Dec. 8, 
2002, at 30; Danna Harman, Some Africans Prefer Hunger to Biotech Corn, DES MOINES REG., 
Nov. 20, 2002, at A1.  
 17. See, e.g., Rachel L. Swarns, African Food Shortages Ending Everywhere Except 
Zimbabwe, N.Y. TIMES, Jan. 31, 2003, at A16.  
 18. See, e.g., Philip Brasher, Activists Push Fear of Food, DES MOINES REG., Aug. 31, 
2002, at 1A. The situation created great opportunity for sermonizing by U.S. proponents of 
biotechnology on the theme of how could a country choose to let its citizens starve rather than 
accept this wonderful gift from the West. See, e.g., Tim Burrack, Safe, GM Food Can Save 
Starving Africans, DES MOINES REG., Nov. 8, 2002, at 13A. 
 19. See Elizabeth Becker, U.S. Threatens to Act Against Europeans over Modified Food, 
N.Y. TIMES, Jan. 10, 2003, at A4.  
 20. Id. 
Washington University Open Scholarship














II. Consumer Acceptance of GMOs—So Far So Good, but What 
About These Fish 
The most significant story relating to the consumption of GMO 
foods in the United States is, in many regards, the lack of a story. For 
the most part, American consumers don’t seem to mind or care. 
When the FDA in January 2001 rejected for the latest and probably 
last time requests to require mandatory labeling of GMO foods, what 
little steam remained went out of this effort.21 Instead, much of the 
attention of GMO opponents has shifted to fighting a rear-guard 
action to protect at least the availability of a food supply that is as 
free as possible of the presence of GMOs. The final approval of the 
USDA’s national organic program standards and labeling 
requirements provided the focus for efforts to develop and expand 
this “alternative” food stream. Because the rules do not allow the use 
of biotechnology for organics, this provides an outlet for consumers 
seeking these foods.22 From the perspective of American law, the 
FDA action rejecting labels for GMO foods flows from the agency’s 
view of the purpose of food labels and the legal conclusion that this 
information is not material and labels not containing it are not 
misleading.23  
 21. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706 (Jan. 18, 
2001) (to be codified at 21 C.F.R. pts. 192 & 592). For a general discussion of U.S. regulation 
of GM foods, see Judith E. Beach, No “Killer Tomatoes”: Easing Federal Regulation of 
Genetically Engineered Plants, 53 FOOD & DRUG L.J. 181 (1998).  
 22. National Organic Program, 7 C.F.R. § 205 (2004); see also Elizabeth Becker, Organic 
Gets an Additive: A U.S.D.A. Seal to Certify It, N.Y. TIMES, Oct. 21, 2002, at A10; A New 
Organic Era, N.Y. TIMES, Oct. 21, 2002, at A18. Unfortunately, in recent weeks the integrity of 
the new national organic program has been placed in jeopardy because of a rider in the 2003 
omnibus spending bill, inserted at the request of Congressman Nathan Deal of Georgia. This 
rider would allow meat to be labeled as organic even if the animals were not fed organic feed, 
even though the price of organic feed is more than double the price of conventional feed. The 
inclusion of this loophole has triggered a new wave of concern and support for protecting the 
organic food label and could produce a backlash that will reignite concerns about the presence 
of GMOs in the food supply. See, e.g., Staying Organic, N.Y. TIMES, Mar. 5, 2003, at A22.  
 23. For a detailed analysis and criticism of the U.S. approach toward the regulation and 
labeling of GMO foods, see Thomas McGarity & Patricia I. Hansen, Breeding Distrust: An 
Assessment and Recommendations for Improving the Regulation of Plant Derived Genetically 
Modified Foods (Jan. 11, 2001), available at http://biotech-info.net/breeding_distrust.html (Jan. 
11, 2001). 
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The most contentious episode in the United States over GMO 
labels was a ballot initiative in Oregon, where a coalition of 
consumer advocates and environmentalists placed a proposal to 
mandate labeling for GMO foods sold in Oregon on the fall 2002 
ballot.24 The food and biotech industry waged a multi-million dollar 
campaign to defeat the initiative and the United States government 
took the unprecedented step of warning the state that it believed such 
a law would interfere with the operation of the national food 
system.25 The combination of ads, warnings, confusion, and other 
uncertainty no doubt helped contribute to the overwhelming defeat 
for the proposal.26 Assuming that the law had passed, food 
manufacturers likely would have challenged it on First Amendment 
grounds as well as claiming federal preemption. Their challenge 
would have been similar to the successful fight waged by the food 
industry to defeat Vermont’s 1994 attempt to require labeling of milk 
produced with bovine growth hormone.27 In that case, the Second 
Circuit Court of Appeals ruled that the First Amendment prohibited 
the state from compelling this type of commercial speech from 
dairies.28 The court observed that consumers concerned about health 
issues could purchase bovine-somatotropin-free milk from producers 
who voluntarily labeled their products as not containing the 
additive.29  
But the assumption that producers who choose to employ 
alternative production techniques are free to communicate this fact on 
 24. For a discussion of the contents of the proposed Oregon law and its potential impact 
on the food industry, see Patricia Callahan, Oregon May Require Labels on Genetic Food, 
WALL ST. J., Sept. 30, 2002, at B1; Elizabeth Weise, FDA Tries to Remove Genetic Label 
Before It Sticks, USA TODAY, Oct. 9, 2002, at 7D (concerning a letter from the acting 
commissioner of the FDA to the Governor of Oregon). 
 25. Brasher, supra note 3. 
 26. Id. 
 27. Int’l Dairy Foods Assoc. v. Amestoy, 92 F.3d 67 (2d Cir. 1996). 
 28. Id. at 72. 
 29. The court stated: 
Absent, however, some indication that this information bears on a reasonable concern 
for human health or safety or some other sufficiently substantial governmental 
concern, the manufacturers cannot be compelled to disclose it. Instead, those 
consumers interested in such information should exercise the power of the their purses 
by buying products from manufacturers who voluntarily reveal it. 
Id. at 74. 
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food labels is not so clear. Farmers and consumers face numerous 
obstacles in their voluntary effort to label foods as being produced 
without GMO ingredients. A food marketer’s ability to label a food 
product in this manner is subject to the FDA’s “voluntary guidance” 
relating to such labels.30 While the guidance appears to provide the 
basis for making such claims, the actual provisions make it next to 
impossible for food marketers to do so, short of complying with 
existing standards for organic food labeling, which is a separate, 
more costly and cumbersome system. While the details of that 
guidance are beyond this paper, suffice it to say that the FDA has 
ruled it is misleading to use the terms “GM” or “GMO free” in such 
labels and has placed the burden of proof on those who label their 
foods as being free of the products of bioengineering.31 The guidance 
further warns that even a “statement that a food was not 
bioengineered or does not contain bioengineered ingredients may be 
misleading if it implies that the labeled food is superior to foods that 
are not so labeled.”32 
The effect of the guidance and the goal of the food industry 
officials who requested it is not to promote voluntary labeling of 
GMO products, a label that while allowed is not found in the 
marketplace; instead, the purpose is to prevent the development of a 
GMO-free food sector.33 By forcing those who want to market or 
purchase GMO-free foods to buy certified organic food, the food 
industry is able to prevent the proliferation of foods marketed as 
GMO-free and limit development of consumer awareness or curiosity 
about the presence of GMO ingredients. This approach to labeling is 
a marked contrast to the true “consumer right to know” approach 
such as that used in Europe.34 One legal uncertainty that may threaten 
the success of this effort is that food industry initiatives use First 
 30. Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have or Have 
Not Been Developing Using Bioengineering, 66 Fed. Reg. 4839 (Jan. 21, 2001), available at 
http://www.cfsan.fda.gov/~dms/biolabgu.html. 
 31. Id. 
 32. Id. 
 33. For the development of the guidance, see Food Industry Groups Petition FDA for 
Guides on Biotechnology-Free Claims, FOOD SAFETY REP., May 10, 2000, at 586.  
 34. For an discussion of the legal rational behind this view, which rejects the notion there 
is a “consumer right to know” under American food law, see Frederick H. Degnan, The Food 
Label and the Right-to-Know, 52 FOOD & DRUG L.J. 49 (1997).  
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Amendment claims to free food marketers from the restraints of FDA 
regulations. Claims that have found support in the federal courts may 
place in doubt the government’s ability to prohibit food marketers 
from making truthful and non-misleading claims about the lack of 
GMO ingredients. But that battle has yet to be fought.35  
Before turning from the food safety and consumer acceptance 
issue, it is important to note that at least one category of food 
continues to raise legitimate consumer and even scientific concerns: 
meat and fish.36 While most of the debate about the use of GM 
technology has related to crops, there are policy issues relating to the 
adequacy of the federal rules relating to animals. In particular, there 
are policy issues relating to the possible sale of genetically 
engineered salmon.37 In August 2002, a panel of the National 
Research Council issued a report recommending that the FDA 
examine the use of gene-altered animals in food production.38 The 
recent incident in which the University of Illinois allegedly sold 
genetically engineered pigs, an illegal act under the FDA 
experimental guidelines, brought the issue of GM meat and the 
integrity of FDA regulation of GM experimentation back to the 
 35. See generally Pearson v. Shalala, 164 F.3d 650, 654–60 (D.C. Cir. 1999) (concerning 
the First Amendment limitations on the ability of FDA to regulate health claims in the 
marketing of dietary supplements and favoring disclaimers over prohibitions); Thompson v. W. 
States Med. Ctr., 535 U.S. 357 (2002) (limiting the ability of Congress to block advertising 
about drug compounding). This expanded view of First Amendment protections for commercial 
speech led the FDA to initiate a process to re-evaluate the scientific standards used to approve 
health claims for foods. See Request for Comments Notice, 67 Fed. Reg. 34,942 (May 16, 
2002); Gina Kolata, Stung by Courts, F.D.A. Rethinks Its Rules, N.Y. TIMES, Oct. 15, 2002, at 
F1; FDA Moves Ahead on Qualified Health Claims with Creation of Task Force, 5 FOOD 
REGULATION REP. 32, Jan 22, 2003, at 3.  
 36. See, e.g., Jennifer L. Brown, Ranchers Await FDA Decision on Cloned Bulls’ Beef, 
DES MOINES REG., Jan. 18, 2003, at D1; Andrew Pollack, Cloned Cows Are Engineered to 
Speed Up Quicker Cheese Making, N.Y. TIMES, Jan. 27, 2003, at A20.  
 37. See Andrew Pollack, Study Faults U.S. on Assessing Altered Fish, N.Y. TIMES, Jan. 
15, 2003, at A16. The article concerns a report by the Pew Initiative on Food and 
Biotechnology which questions the adequacy of the FDA regulations for assessing the risks 
related to the production of genetically modified salmon. See PEW INITIATIVE ON FOOD AND 
BIOTECHNOLOGY, FUTURE FISH: ISSUES IN SCIENCE AND REGULATION OF TRANSGENIC FISH, 
available at http://pewagbiotech.org/research/fish (last visited Nov. 7, 2004). 
 38. NATIONAL RESEARCH COUNCIL, ANIMAL BIOTECHNOLOGY: SCIENCE-BASED 
CONCERNS (2002); see also Warren E. Leary, Panel Urges Caution in Producing Gene-Altered 
Animals, N.Y. TIMES, Aug. 21, 2002, at A12; Ranking Risks of Gene-Altered Animals, N.Y. 
TIMES, Sept. 4, 2002, at A20. 
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public’s attention.39 In addition to lingering concerns about the 
wisdom of using GM technology in meat animals, there was at least 
one reported incident that raised concerns about possible food safety, 
or at least animal safety, of GM technology. In the summer of 2002, 
an interesting story emerged from Iowa concerning the possible 
relationship between fertility problems in swine and the usage of 
certain strains of Bt corn in feed.40 Opponents looking for the 
smoking gun of health problems from using GMO crops hoped the 
story would prove to be a major controversy.41 For scientists, the 
controversy raised several difficult and perhaps unanswerable 
questions. But the official response was that the problems were 
caused by the farmers, not the crops.42  
III. StarLink—Biotech’s Self-Inflicted Black Eye Illustrates Limits of 
Regulatory Structures 
The one incident in the last two years that most clearly illustrates 
the legal and policy dimensions of the biotechnology age is the 
StarLink affair. What begin as a minor incident of some GM corn 
appearing in taco shells blossomed into a major episode that brought 
into focus a range of significant issues, including, among others:  
• the research and marketing decisions of biotech companies;  
 39. See Andrew Pollack, F.D.A. Says Food Supply May Contain Altered Pigs, N.Y. 
TIMES, Feb. 6, 2003, at A26; Elizabeth Weise, Research Piglets Sold as Food Hard to Find, 
USA TODAY, Feb. 7, 2003, at A3.  
 40. See, e.g., Tom Block, More Iowa Sow Herds Experiencing Breeding Problems, IOWA 
FARM BUREAU SPOKESMAN, May 18, 2002, at 1; Tom Block, Pseudopregnancies Puzzle Swine 
Producer, IOWA FARM BUREAU SPOKESMAN, Apr. 29, 2002. John Otte, Swine 
Pseudopregnancy Mystery, HOG PRODUCER, June 2002, at H1. For the biotech, industry the 
issue was a concern, but for conspiracy theorists who believe GMO foods are a serious health 
threat, the story was heaven-sent. Even in light of what appears to be growing acceptance of the 
safety of GMO foods, some organizations continue to point out that questions remain. See, e.g., 
Justin Gillis, FDA Policies for Gene-Altered Foods Faulted in Report, WASH. POST, Jan. 7, 
2003, at A5 (discussing the recent report by the Center for Science in the Public Interest 
concerning gaps in the regulatory system relating to biotechnology).  
 41. For example, Friends of the Earth, which had been responsible for exposing the 
StarLink contamination of corn products, took a special interest in this controversy and the 
disposition of a supply of corn from an Iowa farm. See http://foe.org/camps/comm/safefood/ 
gefood/iowa (last visited Jan. 5, 2004). 
 42. See Researchers Dispute Claims Against Corn, DES MOINES REG., Oct. 11, 2002, at 
2A. 
https://openscholarship.wustl.edu/law_journal_law_policy/vol17/iss1/4














• the adequacy of the U.S. regulatory system for marketing 
GMO products;  
• the cavalier attitudes some seed companies and farmers have 
toward use of GMOs;  
• the ability of the legal system to develop and apply rules for 
allocating liability in cases of unintentional product 
contamination;  
• the difficulty of developing marketing systems to segregate 
products not approved for use throughout America’s food 
system; 
• the role that the government should play in protecting the 
integrity of the grain supply; 
• the inherent tension between the interests of the food industry 
and the interests of the biotech community over the use and 
proliferation of products that raise regulatory and consumer 
acceptance risks; and  
• the impact of such products on export markets for American 
crops.  
The list of issues triggered by the StarLink affair shows how this 
area of American law and policy is still developing. The legacy of the 
StarLink affair can be seen in the court rulings and litigation 
allocating the costs and damages from the incident, proposals for 
state legislation to address GMO contamination, and new regulatory 
proposals to restrict the use of similar technologies.43  
When boiled down to its essence, the StarLink affair resulted from 
the combination of a foolish (and in retrospect incredibly costly) 
decision by Aventis to bring to the market a corn product not 
approved for both food and feed uses and the unreasonable decision 
of the Environmental Protection Agency (EPA) to allow such split 
registration. These two actions were especially unfortunate in light of 
the inability of the grain market to provide for the segregation of the 
crops, and the apparent unwillingness of some of the companies 
marketing the technology to communicate and enforce the limitations 
 43. For an article discussing many of the possible legal theories available to resolve pollen 
drift related damages akin to the StarLink affair, see Amelia P. Nelson, Legal Liability in the 
Wake of StarLink: Who Pays in the End?, 7 DRAKE J. AGRIC. L. 241 (2002).  
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on its use to farmers. Given this background it was entirely 
predictable that StarLink corn would find its way into the food 
supply. When the history of the StarLink affair is written, it will 
reveal many lessons. One important lesson is that without the brave 
actions of lawyers in the Iowa Attorney General’s Farm Division, 
who stepped in to prevent the seed companies’ initial attempts to 
unreasonably allocate the costs and liabilities to the “offending” 
farmers (many of whom had never seen the restrictive terms of the 
product approval) the whole episode may have evolved quite 
differently. These and other lessons should make the StarLink 
episode a powerful and highly instructive moment for all concerned. 
Whether we will be wise enough to be so educated is yet to be seen.  
A key question raised by the StarLink episode is whether we will 
take additional steps to insure that crops not approved for use in 
certain markets will in fact be kept from them. The current approach 
relied on by biotech companies is to place most of this responsibility 
on the producers. This is done by placing language in the technology 
transfer agreement to make producers responsible for post harvest 
“channeling.” For example, the provision used in the Grower’s Copy 
of the “2002 Monsanto Technology/Stewardship Agreement” 
provides, in part: 
Channeling: Grain/commodities harvested from Roundup 
Ready corn, YieldGard Corn Borer with Roundup Ready corn, 
Roundup Ready canola and Roundup Ready sugarbeets are 
approved for U.S. food and feed use, but not yet approved in 
certain export markets where approval is not certain to be 
received before the end of 2002. As a result, the grower is 
required to direct such grain/commodities to the following 
approved market options: feeding on farm, use in domestic 
feed lots, elevators that agree to accept the grain, or other 
approved uses in domestic markets only.44  
In the “you agree” portion of the contract, the grower agrees “[t]o 
channel grain produced to domestic use as necessary to prevent 
 44. See 2002 Monsanto Technology / Stewardship Agreement (on file with author).  
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movement to markets where the grain has not yet received regulatory 
approval for import.”45 
IV. Pharming—New Crops Present Practical Challenges to 
Protecting the Food Supply and Promise New Round of Legal Issues 
No doubt the biggest story in the last year in agricultural 
biotechnology circles has been the attention given to the idea of 
pharming: the production of genetically modified crops engineered to 
express some form of a pharmaceutically useful product. This “new” 
form of biotechnology has received considerable attention in the farm 
press and has generated a seemingly unrealistic set of economic 
expectations by Midwestern farmers and politicians.46 From a legal 
standpoint, the development of pharming raises a whole new set of 
legal and policy issues, primarily because of legitimate concerns 
about the food safety risks of using food crops to produce drugs and 
the liability issues this will produce. Because of the nature of the 
risks, pharming has helped illuminate some of the fault lines that 
exist in the larger food system, perhaps as best illustrated by the 
tensions between food manufacturers (who remember well the costs 
and public relations impact of the StarLink episode) and the farming 
and biotech communities, both of which appear to have never met a 
technology they don’t think should be widely available and utilized.47 
To date, the food sector has been supportive of the development and 
use of agricultural biotechnology. Perhaps this is due to its own 
doctrinal resistance to government regulation. Remarkably, the 
pharma-crop situation has led the National Food Processors 
 45. Id. 
 46. Id. The hoped for economic returns to farmers from pharma-crops may run aground 
on three shoals of industrialized agriculture: the number of acres actually needed for their 
production may be limited; the increased prices paid to farmers may be minimal because they 
did not contribute to the invention of the technology, but instead are only providing land and 
services; and the additional costs and risks associated with raising the crops and meeting the 
regulatory requirements for production will reduce the benefits. The reality is that there is little 
reason to expect pharma-crops to provide returns any larger than conventional crops.  
 47. For example, a General Mills executive speaking on a biotech panel in Chicago 
warned that food manufacturers receive no benefit from the current technology, noting, 
“candidly, we have told the biotech industry that we are in a perilous situation until consumer 
benefits arrive.” Ameet Sachdev, Biotech “Perilous” for Food Industry, DES MOINES REG., 
June 20, 2002, at 1A.  
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Organization to propose a moratorium on the use of the technology 
until the possible risks of contamination of the food supply can be 
addressed.48 This came after the surprising offer by the biotechnology 
industry to limit the use of the technology in large parts of the 
country.49  
The public debate over the production of pharma-crops and the 
adequacy of their regulations began in the summer of 2002, when a 
coalition of environmental groups, GE Food Alert, raised concerns 
about the safety of the technology and the adequacy of the USDA’s 
effort to police the field experiments underway.50 After these 
concerns became public, rumors of possible government actions 
against companies that raised the crops under experimental field 
permits emerged. The issue revolved around whether the companies 
followed agency guidelines that were designed to insure that no 
pollen from the crops drifted into neighboring fields and that 
precautions were taken to see that volunteer crops did not emerge the 
next year.51  
While these rumblings were heard in farm country, the biotech 
industry stunned its supporters in the Midwest, especially in Iowa, by 
launching what amounted to a pre-emptive strike in an attempt to 
head off public concerns about possible contamination of the food 
supply with drugs. In late October, the Biotechnology Industry 
Organization (BIO) members announced a voluntary agreement to 
redline much of the Midwestern corn belt and not plant pharma-corn 
in these areas to avoid possible contamination within the food 
supply.52 The surprise announcement caused difficulty for Governor 
 48. See Anne Fitzgerald, Coalition Urges More Attention to Food Safety, DES MOINES 
REG., Feb. 8, 2003, at D1. This article concerns the coalition led by the Grocery Manufacturers 
of America and their petition to the FDA for stringent regulation of pharma-crops, using the 
same approach as with brick and mortar drug manufacturing facilities. Their proposal included 
requests that the FDA prohibit the use of corn and other food crops for production of plant 
based drugs and a request that the USDA stop issuing field trial permits for the crops. Id. 
 49. See, e.g., Philip Brasher, Iowa Denied New “Drug” Corn, DES MOINES REG., Oct. 23, 
2002, at 1A. 
 50. See, e.g., Anne Fitzgerald, Critics: Altered Crops Pose Risk to Health, DES MOINES 
REG., July 12, 2002, at 1D.  
 51. See, e.g., Anne Fitzgerald, Pioneer Fined for Violating Biotech Corn Permits, DES 
MOINES REG., Dec. 13, 2002, at 1D (concerning fines the EPA assessed to Pioneer and Dow 
AgroSciences for violation of requirements on growing experimental crops).  
 52. See Brasher, supra note 49. 
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Vilsack in his Iowa re-election campaign and illustrated the split 
between the food manufacturers and the biotech industry.53 The 
sudden action by the biotechnology industry led to editorials and a 
public relations campaign to get the policy reversed.54 The industry 
action brought into question the future of biotech plantings and 
research at universities like Iowa State, which had made considerable 
investments in its Plant Sciences Institute.55 The industry eventually 
agreed to lift the moratorium and comply with the federal 
government’s new enhanced rules.56 But the adequacy of the federal 
rules on pharma-crops next came into focus in what came to be 
known as the ProdiGene incident. 
In late 2002, the enforcement of federal rules on the planting of 
biotech crops was brought into focus in a pharming case involving 
the Texas company ProdiGene.57 Facts indicate that the company had 
failed to adequately enforce its field cleanup requirements on two 
sites in Nebraska and Iowa. This led the government to assess a three 
million dollar fine against the company, part of which was to cover 
the cost of the 500,000 bushels of contaminated grain the government 
had to purchase and incinerate.58 The dispute, following on the heels 
of the BIO “redlining” proposal, brought extra focus on the adequacy 
of the federal regulatory structure.59 As a result of the ProdiGene 
incident, the FDA took a renewed interest in the adequacy of its rules 
and, in mid-November, announced plans to increase the monitoring 
of the companies involved in pharming research.60  
 53. See, e.g., Editorial, Lift the Moratorium, DES MOINES REG., Oct. 25, 2002, at 14A. 
 54. See, e.g., Lift the Moratorium, DES MOINES REG., Oct. 25, 2002, at 14A. 
 55. See Philip Brasher, ISU Vows Biotech Research Will Go On, DES MOINES REG., Oct. 
25, 2002, at 1A. 
 56. See, e.g., Philip Brasher, Biotech Group Lifts Corn Ban, DES MOINES REG., Dec. 4, 
2002, at 1A; Bring on “Biopharming”, DES MOINES REG., Dec. 5, 2002, at 12A. 
 57.  Press Release, United States Department of Agriculture, USDA Announces Actions 
Regarding Plant Protection Act Violations Involving Prodigene, Inc. (Dec. 6, 2002), available 
at http://www.usda.gov/news/releases/2002/12/0498.htm (last visited Nov. 7, 2004). 
 58. See Andrew Pollack, U.S. Investigating Biotech Contamination Case, N.Y. TIMES, 
Nov. 13, 2002, at C7; Philip Brasher, Biotech Corn May Have Tainted Soybeans, DES MOINES 
REG., Nov. 13, 2002, at 1A. 
 59. See, e.g., Philip Brasher, Prodigene Must Pay $3 Million in Corn Case, DES MOINES 
REG., Dec. 7, 2002, at 1A; Justin Gillis, Tiny Shoots Lead to Big Biotech Headache, DES 
MOINES REG., Dec. 29, 2002, at M1; Andrew Pollack, Spread of Gene-Altered Pharmaceutical 
Corn Spurs $3 Million Fine, N.Y. TIMES, Dec. 7, 2002, at A15.  
 60. See Philip Brasher, FDA to Tighten Biotech Crop Inspection, DES MOINES REG., Nov. 
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V. Intellectual Property Rights and Agriculturally Important Genetic 
Material—Supreme Court Clears Last Doubt 
When I wrote the article in 2000, one cloud on the horizon of the 
application of intellectual property protections to plant genetic 
material was an Iowa case involving a fight between Pioneer Hi-Bred 
International and an agricultural retailer over infringement of 
Pioneers’ patent rights in its corn varieties. The case raised the issue 
of whether the language of the Plant Variety Protection Act (PVPA) 
preempted the ability of the Patent Office to grant patent protection 
for plant varieties such as the corn in dispute. The district and 
appellate courts predictably upheld the patents and ruled that the 
PVPA does not prevent their issuance.61 The courts held that there 
was no conflict and patents on varieties were legal.62 Surprisingly, the 
United States Supreme Court decided to take certiorari in the case 
and hear further arguments.63 To make a long story short, the Court 
heard the case, considered the issues, and in a six to two decision 
reaffirmed what the seed and biotech communities believed all 
along—the PVPA does not preempt granting patents on plant 
varieties.64 This case is significant because it shows that the Court is 
not going to revisit the larger issue concerning the wisdom or legality 
of granting patents on living materials. While other policy issues of 
trade, pollen drift, and regulatory enforcement continue to engage the 
public, the inside baseball aspect of biotechnology continues with 
fights over intellectual property rights between the major players over 
ownership and control of significant parts of the technology.65  
20, 2002, at 1D; Set Tough Rules for Biofarms, DES MOINES REG., Nov. 14, 2002, at 18A. 
 61. Pioneer Hi-Bred Int’l, Inc. v. J.E.M. Ag Supply, Inc., 49 U.S.P.Q.2d 1813 (N.D. Iowa 
1998), aff’d 200 F.3d 1374 (Fed. Cir. 2002). 
 62. Id. 
 63. J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., 534 U.S. 124 (2001). 
 64. Id.; see also Kevin M. Baird, Recent Development, Patent Protection of Plants Grows 
Under the Supreme Court’s Latest Decision, 2002 U. ILL. J.L. TECH. & POL’Y 269 (2002); 
Anne Hazlett, Supreme Court Holds Utility Patents May Be Issued for Plants, AGRIC. L. 
UPDATE, Jan. 2002, at 4, 4–5; Mark D. Janis & Jay P. Kesan, Intellectual Property Protections 
for Plant Innovation: Unresolved Issues After J.E.M. v. Pioneer, 20 NATURE BIOTECH., Nov. 
2002, at 1161. 
 65. See, e.g., David Elbert, Pioneer Sues Rival Over Patent, DES MOINES REG., Oct. 18, 
2002, at 1D; Andrew Pollack, Dispute Ends for Monsanto and DuPont, N.Y. TIMES, Apr. 3, 
2002. 
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From a farmer’s perspective, the most immediate intellectual 
property rights issue is the impact of technology transfer agreements 
and product labeling on the ability to save and replant biotech crops. 
The bottom line is that biotech crops are only marketed under 
arrangements that comprehensively prevent this opportunity (because 
they do not allow leakage of the technology). The legality of these 
agreements has been debated in connection with the Roundup Ready 
technology agreement, but there is little doubt about their 
enforceability. In the last year some of the first court cases 
illuminating the issue have been decided.66 The cases present few 
surprises and hold that the language of the planting restrictions is 
enforceable.67 Of the court cases involving seed patent infringement 
and possible pollen drift, the fight between Canadian farmer Percy 
Schmeiser and Monsanto of Canada concerning his alleged 
infringement on Roundup Ready canola has received the greatest 
attention in the international press.68 The Canadian district court ruled 
that Mr. Schmeiser had infringed upon Monsanto’s rights, rejecting 
Mr. Schmeiser’s theory that the canola came onto his property 
through drift or other unintentional sources.69 In September 2002, the 
Canadian Court of Appeals upheld the decision.70 The case may still 
go up for further appeal. 
VI. State Initiatives to Allocate Responsibility and Liability for Pollen 
Drift—Who Pays for “Adventitious” Presence? 
In my 2000 article, I commented that “[g]enetic pollution or 
“pollen drift’ is perhaps the most intellectually interesting legal issue 
relating to biotechnology.”71 I still believe this is true, although the 
 66. See, e.g., Monsanto Co. v. McFarling, 302 F.3d 1291 (Fed. Cir. 2002); Monsanto v. 
Swann, 308 F. Supp. 2d 937 (E.D. Mo. 2003). 
 67. See, e.g., David Moeller, Monsanto Gets Injunction Against Seed-Saving Farmer, 17 
FLAG NEWSLETTER (Farmers Legal Action Group), Fall 2002, at 9; Donald Uchtmann, Can 
Farmers Save Roundup Ready Beans for Seed? McFarling and Trantham Cases Say “No”, 
AGRIC. L. UPDATE, Oct. 2002, at 4–5. 
 68. Information about this dispute can be found at http://percyschmeiser.com (last visited 
Jan. 5, 2005). 
 69. See Monsanto Canada, Inc. v. Schmeiser, 2001 FCT 256. 
 70. See Schmeiser v. Monsanto Canada, Inc., 2002 FCA 309. 
 71. Hamilton, supra note 1, at 103. 
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development of legal precedent addressing this issue has been 
limited.72 The StarLink litigation and settlement is perhaps the most 
significant development because it establishes responsibility for 
damages resulting from the use of the technology. However, because 
the case involved a violation of the regulatory approval of the 
product, it may not serve as controlling precedent in the more 
difficult case where the lawful use of an approved product results in 
measurable commercial damages to a non-compatible crop. As a 
result, courtroom battles to resolve conflicts over pollen drift from 
the production of GMO crops and the potential liability from 
contaminating neighboring non-GMO crops still loom on the legal 
horizon.73  
State attempts to regulate the actual planting and use of biotech 
crops is another legal front on which several developments have 
occurred. For example, in March 2001, the North Dakota legislature 
considered, but rejected, a proposal prohibiting the planting of GMO 
wheat for two years.74 In 2002, the Indiana legislature passed 
legislation designed to inject state law into the questions of liability 
and responsibility for use of biotech crops.75 In 2003, the Iowa 
General Assembly introduced a new legislative approach to 
addressing pollen drift damages by creating a “Grain Integrity 
Indemnity Fund.”76 This idea, based on the state’s grain indemnity 
fund, which protects farmers who store or sell grain from financial 
losses, would assess a small fee or excise tax on each bushel of grain 
sold in the state to fund a twenty-five million dollar indemnity fund 
to cover validated claims of damages from pollen contamination. 
While the idea can be criticized for failing to allocate the financial 
liability to either the developers of the technology or the actual users, 
the approach has the major benefit of providing an accessible pool of 
 72. For an excellent discussion of many of the dimensions of this issue, as influenced by 
the StarLink affair, see Thomas P. Redick & Christina G. Bernstein, Nuisance Law and the 
Prevention of “Genetic Pollution”: Declining a Dinner Date with Damocles, 30 ENVTL. L. 
REP., May 2000, at 10,328.  
 73. See, e.g., Anne Fitzgerald, Specialty Pollen Concern Blowin’ in Wind, DES MOINES 
REG., Mar. 7, 2002, at 1D. 
 74. See Andrew Pollack, Proposal to Bar Altered Wheat Seems Doomed, N.Y. TIMES, 
Mar. 31, 2001, at A9. 
 75. H.B. 1119, 112th Gen. Assemb., 2d Reg. Sess. (Ind. 2003). 
 76. H.F. 80-108, 1st Sess. (Iowa 2003). 
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funds for compensating injured growers. Instead of requiring each 
dispute to become a courtroom battle over proof of causation and the 
measurement of damages, the indemnity fund approach would give 
farmers what they need most: a way to cover their damages.  
VII. International Trade Restraints on Marketing GMO Crops—
When Will We Be Heard? 
The most contentious area of the biotechnology debate continues 
to be the relationship between the United States and the European 
Union and the issue of European regulations on the importation and 
labeling of American-raised GM crops. While the European Union 
has made progress in developing new standards, perhaps the best way 
to describe the situation in the winter of 2003 was mounting tensions 
moving inexorably toward a WTO trade war.77 The only problem 
from the United States perspective was that another, more important, 
war moved onto center stage. It was politically and diplomatically 
difficult to bash the Europeans over GMO policy while trying to 
motivate them to support our efforts to wage war on Iraq.78 As a 
result, the drumbeat for a trade war with the Europeans over GMO 
policy, which many see as a much-needed test of the resolve and 
efficacy of WTO rules and processes and a defense of sound science, 
has had to take a back seat to more pressing geo-political concerns.79 
Even among those nations embracing biotechnology there exists 
issues relating to free trade in the technology and efforts to protect 
domestic economic opportunities. The situation in China is perhaps 
the best example of this schizophrenic situation: the nation embraces 
the use of biotechnology but uses an uncertain regulatory 
environment to chill the ability of Western companies to export crops 
to the country.80 While Chinese regulations on biotechnology 
 77. See, e.g., Philip Brasher, Fear Threatens U.S. Crop Sales in Europe, DES MOINES 
REG., Nov. 11, 2002, at 1A. 
 78. See Elizabeth Becker, U.S. Delays Suing Europe over Ban on Modified Food, N.Y. 
TIMES, Feb. 5, 2003, at A6.  
 79. See Philip Brasher, Biotech Ban Tries Patience of U.S., DES MOINES REG., Mar. 4, 
2003, at 1D. 
 80. See Joseph Kahn, The Science and Politics of Super Rice, N.Y. TIMES, Oct. 22, 2002, 
at C1. 
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continue to evolve and raise concerns for United States exports, some 
American companies have been able to develop plans for moving 
forward with China.81  
IX. Resistance and GMOs—Refuges, Roundup and Resistant Weeds 
From a technological standpoint, one significant issue related to 
the widespread adoption of GMO technology is how its use will 
eventually lead to the development of resistance in the target pest. 
From a regulatory perspective, this concern is most directly at issue 
in the regulation of bio-pesticides such as Bt corn. The regulatory 
focus is on the need for farmers to follow resistance management 
plans, which include planting non-Bt refuges. The counter-intuitive 
nature of requiring farmers not to use an effective technology and the 
unwelcome task of actually enforcing regulations relating to refuges 
help complicate this topic. In late November 2002, the EPA 
announced a “two-strikes” policy concerning farmer compliance with 
the field refuge requirements for planting Bt corn, including roles for 
companies to aid in the enforcement.82 The issue of resistance 
management took another turn early in 2003, when new research was 
reported indicating the increased appearance of weeds resistant to the 
use of Roundup.83 The significance of the story was emphasized 
when it became the subject of a somewhat surprising editorial, 
entitled “Too Much Roundup.”84  
CONCLUSION: THE FUTURE OF LAW AND BIOTECHNOLOGY 
This article provides a concise update of many of the significant 
legal and policy issues shaping American law as relates to 
agricultural biotechnology. Some issues, such as the international 
bio-safety protocol and the recent completed international agreements 
 81. See, e.g., Anne Fitzgerald, Joint-Venture to Produce, Sell Seed Corn to Chinese 
Farmers, DES MOINES REG., Dec. 12, 2002, at 1D (concerning a recent agreement between 
Pioneer Hi-Bred International and a major Chinese seed corn company). 
 82. See Philip Brasher, Rules Govern Biotech Planting, DES MOINES REG., Nov. 27, 2002, 
at D1. 
 83. Philip Brasher, Roundup-Resistant Weeds Are Cropping Up All Over, DES MOINES 
REG., Jan. 10, 2003, at A1.  
 84. Too Much Roundup, INT’L HERALD TRIB., Feb. 20, 2003, at 8.  
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on plant genetic resources, were beyond the scope of this discussion. 
Other areas of ongoing litigation, such as the StarLink settlement, 
could be the basis for their own lengthy treatment. What is clear from 
this discussion is that a series of significant legal and policy questions 
will continue to shape how agricultural biotechnology will be 
accepted in America. As the article makes clear on the issue of food 
safety and consumer acceptance, unless some new incident occurs to 
provide evidence of safety concerns, the marketplace will continue to 
welcome GMO foods. In the near term, one of the most significant 
issues is whether genetically altered salmon will be marketed, and if 
so, what type of environmental restrictions will be placed on its 
production. From the perspective of farmers and state legislators, the 
future of pharma-crops will offer both promise and problems. It will 
be interesting to see whether the market reality for the crops can 
match the expectations they appear to be generating. On the 
international front, the tension between the United States and the 
European Union over GMOs will remain a source of conflict that 
may or may not be addressed when the European Union approves its 
long-promised policy on the production of GMO crops. 
Biotechnology is a powerful and elegant technology that will 
undoubtedly play a role in the future of world agriculture. The 
complex social issues relating to biotechnology will test the ability of 
the legal system to develop rules and mechanisms to guide its use. 
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